Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Posted by Casey Walker on May 26th, 2026

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $25.37, but opened at $23.7101. Chugai Pharmaceutical shares last traded at $23.81, with a volume of 27,262 shares traded.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CHGCY. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, Chugai Pharmaceutical presently has a consensus rating of “Strong Buy”.

Check Out Our Latest Report on Chugai Pharmaceutical

Chugai Pharmaceutical Stock Performance

The company has a market cap of $78.57 billion, a PE ratio of 26.52 and a beta of 0.63. The company has a 50 day simple moving average of $26.61 and a two-hundred day simple moving average of $27.35.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.